The Effects of Vonoprazan Fumarate on DGF Incidence in DD Kidney Transplant Recipients

NCT07275632 · tracked via the Priya Life Science China tracker

Sponsor

First Affiliated Hospital of Chongqing Medical University

Phase

Phase 1/2

Started

2025-12-10

Last updated

2025-12-23

Condition(s) studied

Delayed Graft FunctionKidney Transplantation

Investigational drug(s) / intervention(s)

Vonoprazan fumarate

Vonoprazan fumarate: Phase Ib: A dose escalation study will be initiated with vonoprazan fumarate 20 mg once daily (qd). Two dose groups are planned: 20 mg qd and 20 mg twice daily (bid). According to a "3+3" dose escalation scheme, the first three subjects will receive vonoprazan fumarate 20 mg qd orally, starting on the day of kidney transplantation and continuing until postoperative day 7. Safety and tolerability will be assessed from the day of transplantation through postoperative days 7 and 28. Phase II: An expansion study will be conducted at the recommended Phase II dose of vonoprazan fumarate to evaluate the efficacy, safety, and tolerability of the regimen. Vonoprazan fumarate will be administered orally, starting on the day of kidney transplantation and continuing daily until postoperative day 7. Throughout both the Phase Ib and Phase II stages, all recipients will receive the center's standard immunosuppressive regimen.

Study summary

This is an exploratory, multicenter, single-arm study designed to evaluate the efficacy of perioperative Vonoprazan Fumarate in reducing the incidence of Delayed Graft Function (DGF) in deceased-donor kidney transplant recipients. DGF is a common early complication that significantly impacts graft function and long-term transplant survival. This study aims to explore how Vonoprazan Fumarate, a potassium-competitive acid blocker (P-CAB), can potentially improve macrophage phagocytic function, reduce kidney inflammation, and enhance early kidney function recovery.

Patients aged 18 years and older who are undergoing first-time deceased-donor kidney transplantation will be enrolled. Vonoprazan Fumarate will be administered daily starting on the day of transplantation and continuing for seven days post-surgery. The primary endpoint is DGF incidence, while secondary endpoints include kidney function recovery, serum creatinine reduction, estimated glomerular filtration rate, and safety assessments. Adverse events will be monitored, and the study will also explore potential biomarkers for inflammation and graft function.

The study is expected to provide insights into a potential new therapeutic strategy to reduce DGF and improve early kidney transplant outcomes, potentially benefiting future kidney transplant patients by offering a safer and more effective perioperative treatment option.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Age ≥ 18 years at time of transplantation. * Undergoing first-time deceased-donor kidney transplantation. * No administration of proton-competitive acid blockers (P-CABs) in the 1 month prior to transplantation. * Consent to receive the standard immunosuppressive therapy post-transplantation. * Ability and willingness to provide informed consent and comply with study procedures and follow-up. * Complete baseline clinical data available. Exclusion Criteria: * Receiving a living-donor kidney transplant or multi-organ transplantation. * Previous history of any solid organ or cellular transplantation (with the exception of corneal transplants). * Intraoperative occurrence of hyperacute rejection or confirmed graft non-function (e.g., renal artery thrombosis). * Presence of high risk for primary graft non-function (e.g., severe injury to the transplant renal artery). * Severe postoperative intestinal obstruction requiring prolonged fasting or inability to take oral medication in perioperative period. * Known history of hypersensitivity to vonoprazan fumarate or any of its excipients. * Subjects with severe hepatic impairment (Child-Pugh Class C). * Concomitant use of strong CYP3A4 inhibitors (e.g., ritonavir, clarithromycin). * Current therapy with atazanavir or rilpivirine. * Any other condition deemed by the investigator to be inappropriate for study participation (e.g., uncontrolled active infection, severe peptic ulcer, pregnancy or lactation).

Primary outcome measure(s)

Incidence of Delayed Graft Function (DGF) — Within the first 7 days post-transplant
Delayed Graft Function (DGF) is defined as the requirement for any form of dialysis (hemodialysis or peritoneal dialysis) due to renal insufficiency within the first week after kidney transplantation.

Trial sites (2)

Facility	City	Region	Status
The First Affiliated Hospital of Chongqing Medical University	Chongqing	China	Recruiting
Sun Yat-sen Memorial Hospital, Sun Yat-sen University	Guangzhou	China	Not Yet Recruiting

More First Affiliated Hospital of Chongqing Medical University trials in China

Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment Recruiting

Sertraline Combined With Multi-Strain Probiotics for Adolescent Depression Recruiting

Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study Starting soon

Metabolomics Predictors for Metabolic Disease Remission After Metabolic Syndrome Surgery. Active, not recruiting

An Integrated Multi-omics Study on the Molecular Mechanisms of Ureteral Stricture Starting soon

Other trials for the same condition

Artificial Intelligence Model for Renal Allograft Rejection Identification, Lesion Quantification and Rejection Risk Prediction Based on Prospective Renal Transplant Pathology and Clinical Multidimensional Data Active, not recruiting

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation Recruiting

Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation Active, not recruiting

Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation Active, not recruiting

Muscle Ultrasound for Sarcopenia Assessment in Kidney Transplant Recipients Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07275632 on ClinicalTrials.gov ↗ ← All trials in China